Please login to the form below

Not currently logged in
Email:
Password:

advanced breast cancer

This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

negative metastatic breast cancer, ”said Joyce O'Shaughnessy, chair of the breast cancer research programme for Baylor University Medical Center, in a press release. ... This information will help inform treatment decisions for each patient, which can

Latest news

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    AstraZeneca and Merck &Co have been awarded FDA approval for Lynparza in BRCA-positive advanced breast cancer - the first drug in the PARP inhibitor class to be approved outside ovarian cancer. ... The drug can also be used in hormone receptor-positive

  • Novartis bags new breakthrough status for Kisqali in breast cancer Novartis bags new breakthrough status for Kisqali in breast cancer

    The BTD is based on the results of the MONALEESA-7 trial, which involved pre-menopausal women with hormone-receptor positive, HER2-negative advanced breast cancer and was the first to ... If approved in younger women with advanced breast cancer, Kisqali

  • NICE set to reject wider use of Eisai’s Halaven NICE set to reject wider use of Eisai’s Halaven

    The UK health technology assessment agency says there is a lack of evidence that Halaven offers value for money in locally-advanced or secondary breast cancer in patients who have previously ... Advanced breast cancer patients are generally offered an

  • NICE backs two advanced breast cancer drugs after price cuts NICE backs two advanced breast cancer drugs after price cuts

    NICE backs two advanced breast cancer drugs after price cuts. An estimated 8, 000 women will be eligible to receive the drugs due to discounts. ... important breakthroughs for women with advanced breast cancer in the last two decades”.

  • Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

    The MONALEESA-7 trial in pre-menopausal women with hormone-receptor positive, HER2-negative advanced breast cancer is the first dedicated study to show a benefit for a CDK4/6 blocker ... There remains a significant unmet treatment need in younger women

More from news
Approximately 1 fully matching, plus 143 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being

  • Digital disruption Digital disruption

    Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... This would complement Pfizer's palbococlib, launched in the US in February 2015, to treat HR+/HER2 metastatic

  • Pharma deals during July 2014 Pharma deals during July 2014

    Seragon's focus is in hormone dependent cancers and specifically the development of its Selective Estrogen Receptor Degrader (SERD) platform of oral, small molecule therapeutics for breast and other cancers. ... The lead SERD compound, ARN-810, is

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... Palbociclib, which is the result of an early

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • FALCON trial of fulvestrant for advanced breast cancer

    FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics